Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2023-02-22 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 1% confidence The document is a formal notification of transactions in company shares made by a managerial employee (the CEO, Jan G. J. van de Winkel). It explicitly references Article 19 of Regulation No. 596/2014 on Market Abuse, which is the standard regulatory framework for reporting insider dealings. This falls directly under the 'Director's Dealing' category.
2023-02-22 English
20-F
Annual Report FY 2022
2023-02-22 English
6-K
Foreign Filer Report
2023-02-22 English
6-K
Foreign Filer Report
2023-02-22 English
Transaction in Own Shares 2023
Transaction in Own Shares Classification · 1% confidence The document is titled "Genmab Announces Initiation of Share Buy-Back Program" and details the terms, purpose, and timeframe for repurchasing up to 220,000 shares. This action directly relates to the company managing its own stock, specifically through a repurchase program to honor commitments under its Restricted Stock Unit program. According to the definitions, the category for reporting the company buying back or selling its own shares is 'Transaction in Own Shares' (POS). The document is an announcement of this specific corporate action, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains substantive details about the transaction itself.
2023-02-22 English
Genmab Announces Initiation of Share Buy-Back Program
Transaction in Own Shares Classification · 1% confidence The document is an official company announcement regarding the initiation of a share buy-back program. It details the purpose, timeframe, and terms of the repurchase. While it mentions the future issuance of weekly transaction reports, the document itself is the primary announcement of the program's initiation. According to the filing definitions, 'Transaction in Own Shares' (POS) is the specific category for reports of a company buying back its own shares, which encompasses the announcement of such programs.
2023-02-22 Danish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.